AR106314A1 - COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 - Google Patents
COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53Info
- Publication number
- AR106314A1 AR106314A1 ARP160103098A ARP160103098A AR106314A1 AR 106314 A1 AR106314 A1 AR 106314A1 AR P160103098 A ARP160103098 A AR P160103098A AR P160103098 A ARP160103098 A AR P160103098A AR 106314 A1 AR106314 A1 AR 106314A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- aryl
- independently
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
Abstract
La presente solicitud divulga compuestos como inhibidores de la interacción entre MDM2 y p53, composiciones farmacéuticas que contienen compuestos de este tipo, su uso como medicamentos, especialmente, como agentes para el tratamiento y/o la prevención de enfermedades oncológicas e intermediarios sintéticos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), en donde R¹ es un grupo opcionalmente sustituido con uno o más Rᵇ¹ y/o Rᶜ¹, idénticos o diferentes, seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᵇ¹ se selecciona independientemente de -ORᶜ¹, -NRᶜ¹Rᶜ¹, halógeno, -CN, -C(O)Rᶜ¹, -C(O)ORᶜ¹, -C(O)NRᶜ¹Rᶜ¹, -S(O)₂Rᶜ¹, -S(O)₂NRᶜ¹Rᶜ¹, -NHC(O)Rᶜ¹, -N(C₁₋₄ alquil)C(O)Rᶜ¹ y el sustituyente bivalente =O, mientras que =O puede ser únicamente un sustituyente en sistemas de anillos no aromáticos; cada Rᶜ¹, independientemente entre sí, indica hidrógeno o un grupo opcionalmente sustituido con uno o más Rᵈ¹ y/o Rᵉ¹, idénticos o diferentes, seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᵈ¹ se selecciona independientemente de -ORᵉ¹, -NRᵉ¹Rᵉ¹, halógeno, -CN, -C(O)Rᵉ¹, -C(O)ORᵉ¹, -C(O)NRᵉ¹Rᵉ¹, -S(O)₂Rᵉ¹, -S(O)₂NRᵉ¹Rᵉ¹, -NHC(O)Rᵉ¹, -N(C₁₋₄ alquil)C(O)Rᵉ¹ y el sustituyente bivalente =O, mientras que =O puede ser únicamente un sustituyente en sistemas de anillos no aromáticos; cada Rᵉ¹, independientemente entre sí, indica hidrógeno o un grupo opcionalmente sustituido con uno o más Rᶠ¹ y/o Rᵍ¹, idénticos o diferentes, seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᶠ¹ se selecciona independientemente de -ORᵍ¹, -NRᵍ¹Rᵍ¹, halógeno, -CN, -C(O)Rᵍ¹, -C(O)ORᵍ¹, -C(O)NRᵍ¹Rᵍ¹, -S(O)₂Rᵍ¹, -S(O)₂NRᵍ¹Rᵍ¹, -NHC(O)Rᵍ¹, -N(C₁₋₄ alquil)C(O)Rᵍ¹ y el sustituyente bivalente =O, mientras que =O puede ser únicamente un sustituyente en sistemas de anillos no aromáticos; cada Rᵍ¹ se selecciona independientemente de hidrógeno, C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; R² y R³, cada uno independientemente, se selecciona de hidrógeno, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros, en donde C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros están opcionalmente sustituidos con uno o más, Rᵇ² y/o Rᶜ² idénticos o diferentes; cada Rᵇ² se selecciona independientemente de -ORᶜ², -NRᶜ²Rᶜ², halógeno, -CN, -C(O)Rᶜ², -C(O)ORᶜ², -C(O)NRᶜ²Rᶜ², -S(O)₂Rᶜ², -S(O)₂NRᶜ²Rᶜ², -NHC(O)Rᶜ², -N(C₁₋₄ alquil)C(O)Rᶜ² y el sustituyente bivalente =O, mientras que =O puede ser únicamente un sustituyente en sistemas anulares no aromáticos; cada Rᶜ², independientemente entre sí, indica hidrógeno o un grupo opcionalmente sustituido con uno o más Rᵈ² y/o Rᵉ² idénticos o diferentes seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₆ cicloalquilo, C₄₋₆ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᵈ² se selecciona independientemente de -ORᵉ², -NRᵉ²Rᵉ², halógeno, -CN, -C(O)Rᵉ², -C(O)ORᵉ², -C(O)NRᵉ²Rᵉ², -S(O)₂Rᵉ², -S(O)₂NRᵉ²Rᵉ², -NHC(O)Rᵉ², -N(C₁₋₄ alquil)C(O)Rᵉ² y el sustituyente bivalente =O, mientras que =O puede ser únicamente un sustituyente en sistemas de anillos no aromáticos; cada Rᵉ², independientemente entre sí, indica hidrógeno o un grupo seleccionado de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₆ cicloalquilo, C₄₋₆ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; A se selecciona de fenilo y heteroarilo de 5 a 6 miembros si F es carbono o A es heteroarilo de 5 a 6 miembros que contiene nitrógeno si F es nitrógeno; cada R⁴ se selecciona independientemente de Rᵃ⁴ y Rᵇ⁴; cada Rᵃ⁴, independientemente entre sí, es un grupo opcionalmente sustituido con uno o más Rᵇ⁴ y/o Rᶜ⁴, idénticos o diferentes, seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᵇ⁴ se selecciona independientemente de -ORᶜ⁴, -NRᶜ⁴Rᶜ⁴, halógeno, -CN, -C(O)Rᶜ⁴, -C(O)ORᶜ⁴, -C(O)NRᶜ⁴Rᶜ⁴, -C(O)NRᵍ⁴ORᶜ⁴, -S(O)₂Rᶜ⁴, -S(O)₂NRᶜ⁴Rᶜ⁴, -NHSO₂Rᶜ⁴, -N(C₁₋₄ alquil)SO₂Rᶜ⁴, -NHC(O)Rᶜ⁴ y -N(C₁₋₄ alquil)C(O)Rᶜ⁴; cada Rᶜ⁴, independientemente entre sí, indica hidrógeno o un grupo opcionalmente sustituido con uno o más Rᵈ⁴ y/o Rᵉ⁴, idénticos o diferentes, seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᵈ⁴ se selecciona independientemente de -ORᵉ⁴, -NRᵉ⁴Rᵉ⁴, halógeno, -CN, -C(O)Rᵉ⁴, -C(O)ORᵉ⁴, -C(O)NRᵉ⁴Rᵉ⁴, -C(O)NRᵍ⁴ORᵉ⁴, -S(O)₂Rᵉ⁴, -S(O)₂NRᵉ⁴Rᵉ⁴, -NHC(O)Rᵉ⁴ y -N(C₁₋₄ alquil)C(O)Rᵉ⁴; cada Rᵉ⁴, independientemente entre sí, indica hidrógeno o un grupo opcionalmente sustituido con uno o más Rᶠ⁴ y/o Rᵍ⁴, idénticos o diferentes, seleccionados de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; cada Rᶠ⁴ se selecciona independientemente de -ORᵍ⁴, -NRᵍ⁴Rᵍ⁴, halógeno, -CN, -C(O)Rᵍ⁴, -C(O)ORᵍ⁴, -C(O)NRᵍ⁴Rᵍ⁴, -C(O)NRᵍ⁴ORᵍ⁴, -S(O)₂Rᵍ⁴, -S(O)₂NRᵍ⁴Rᵍ⁴, -NHC(O)Rᵍ⁴ y -N(C₁₋₄ alquil)C(O)Rᵍ⁴; cada Rᵍ⁴ se selecciona independientemente de hidrógeno, C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros y heterociclilo de 3 a 10 miembros; r indica el número 0, 1, 2 ó 3; n indica el número 1, 2 ó 3; cada R⁷ se selecciona independientemente de halógeno, C₁₋₄ alquilo, -CN, C₁₋₄ haloalquilo, -OC₁₋₄ alquilo y -OC₁₋₄ haloalquilo; q indica el número 0, 1, 2 ó 3; W, X e Y se seleccionan, cada uno independientemente, de -N= y -CH= siempre que el hidrógeno en cada -CH= se pueda reemplazar por un sustituyente R⁷ si está presente y que un máximo de dos W, X e Y puedan ser -N=; V es oxígeno o azufre; D es nitrógeno, E es carbono y F es carbono; o D es carbono, E es nitrógeno y F es carbono; o D es carbono, E es carbono y F es nitrógeno; o una sal de aquel. Reivindicación 16: Intermediarios sintéticos caracterizados por la fórmula (2), en donde R², R³, R⁴, R⁷, A, V, W, X, Y, r y q son como se definen en cualquiera de las reivindicaciones 1 a 14.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15189210 | 2015-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106314A1 true AR106314A1 (es) | 2018-01-03 |
Family
ID=54292702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103098A AR106314A1 (es) | 2015-10-09 | 2016-10-07 | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 |
Country Status (32)
Country | Link |
---|---|
US (3) | US10144739B2 (es) |
EP (1) | EP3359542B1 (es) |
JP (1) | JP6602470B2 (es) |
KR (1) | KR20180058832A (es) |
CN (2) | CN113214270A (es) |
AR (1) | AR106314A1 (es) |
AU (1) | AU2016333721B2 (es) |
BR (1) | BR112018007155B1 (es) |
CA (1) | CA3000063A1 (es) |
CL (1) | CL2018000666A1 (es) |
CO (1) | CO2018003565A2 (es) |
CY (1) | CY1124284T1 (es) |
DK (1) | DK3359542T3 (es) |
EA (1) | EA036013B1 (es) |
ES (1) | ES2873895T3 (es) |
HK (1) | HK1252365A1 (es) |
HR (1) | HRP20210960T1 (es) |
HU (1) | HUE054985T2 (es) |
IL (1) | IL258073B (es) |
LT (1) | LT3359542T (es) |
MA (1) | MA50065B1 (es) |
MX (1) | MX2018004207A (es) |
PE (1) | PE20181205A1 (es) |
PH (1) | PH12018500763A1 (es) |
PL (1) | PL3359542T3 (es) |
PT (1) | PT3359542T (es) |
RS (1) | RS61936B1 (es) |
SA (1) | SA518391307B1 (es) |
SI (1) | SI3359542T1 (es) |
TW (1) | TWI737635B (es) |
UA (1) | UA123905C2 (es) |
WO (1) | WO2017060431A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
EP3183254B1 (en) | 2014-08-21 | 2019-05-22 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
JP6602470B2 (ja) * | 2015-10-09 | 2019-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mdm2−p53阻害薬としてのスピロ[3h−インドール−3,2‘−ピロリジン]−2(1h)−オン化合物及び誘導体 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
BR112019021032A2 (pt) * | 2017-04-05 | 2020-05-05 | Boehringer Ingelheim Int | terapia combinada anticâncer |
EA202091583A1 (ru) * | 2017-12-29 | 2020-10-08 | Ган Энд Ли Фармасьютикалз | Соединения, которые могут применяться в качестве ингибитора опухоли, способ их получения и их применение |
EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
US20210324478A1 (en) * | 2018-07-18 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators |
US10590147B1 (en) | 2019-09-10 | 2020-03-17 | King Saud University | Spirooxindole-pyrrolothiazole heterocyclic hybrids |
KR20220098755A (ko) * | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
KR20230019462A (ko) | 2020-06-02 | 2023-02-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CN112047951A (zh) * | 2020-10-16 | 2020-12-08 | 吉林大学 | 手性螺[吡咯-2,2’-呋喃]化合物及其制备方法 |
IL310121A (en) | 2021-08-09 | 2024-03-01 | Boehringer Ingelheim Int | A preparation for oral administration that includes an MDM2-antagonist for the treatment of cancer |
WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202337431A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114540A (en) | 1997-09-08 | 2000-09-05 | Arqule, Inc. | Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use |
EA019566B1 (ru) | 2005-02-22 | 2014-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 |
JP2006234861A (ja) | 2005-02-22 | 2006-09-07 | Fujinon Sano Kk | 光学ガラスの製造方法,偏光変換素子の製造方法及び偏光変換素子 |
CA2598956A1 (en) | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
ATE495176T1 (de) | 2006-03-13 | 2011-01-15 | Hoffmann La Roche | Spiroindolinon-derivate |
CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
JP5399904B2 (ja) | 2006-08-30 | 2014-01-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Mdm2の小分子阻害剤およびその使用 |
AR065860A1 (es) | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8134001B2 (en) | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
US20100190814A1 (en) | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
NZ600430A (en) * | 2009-11-12 | 2014-06-27 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
US20120071499A1 (en) * | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
EA201390682A1 (ru) | 2010-11-12 | 2014-01-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
US20130053410A1 (en) | 2011-03-03 | 2013-02-28 | David Joseph Bartkovitz | Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione |
MY172862A (en) | 2011-03-10 | 2019-12-13 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
JP2014513699A (ja) | 2011-05-11 | 2014-06-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | スピロ−オキシインドールmdm2アンタゴニスト |
CN102443004A (zh) * | 2011-11-01 | 2012-05-09 | 南京工业大学 | 有机发光材料6,7,14,15-四氢-5,13-二取代苯并[1,2-c:4,5-c’]二吖啶类化合物、合成方法及应用 |
CN103910746B (zh) * | 2014-02-28 | 2016-08-03 | 中山大学 | 一类海洋真菌来源的Berkeleyones化合物及其制备方法和应用 |
WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
WO2016001376A1 (en) * | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
EP3183254B1 (en) | 2014-08-21 | 2019-05-22 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
NO2721710T3 (es) | 2014-08-21 | 2018-03-31 | ||
JP6602470B2 (ja) * | 2015-10-09 | 2019-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mdm2−p53阻害薬としてのスピロ[3h−インドール−3,2‘−ピロリジン]−2(1h)−オン化合物及び誘導体 |
JP2018017594A (ja) * | 2016-07-27 | 2018-02-01 | セイコーエプソン株式会社 | 動力伝達装置、ロボットおよびプリンター |
-
2016
- 2016-10-07 JP JP2018517748A patent/JP6602470B2/ja active Active
- 2016-10-07 US US15/287,958 patent/US10144739B2/en active Active
- 2016-10-07 PL PL16778038T patent/PL3359542T3/pl unknown
- 2016-10-07 CA CA3000063A patent/CA3000063A1/en active Pending
- 2016-10-07 WO PCT/EP2016/074008 patent/WO2017060431A1/en active Application Filing
- 2016-10-07 EA EA201890888A patent/EA036013B1/ru not_active IP Right Cessation
- 2016-10-07 DK DK16778038.6T patent/DK3359542T3/da active
- 2016-10-07 MX MX2018004207A patent/MX2018004207A/es active IP Right Grant
- 2016-10-07 LT LTEP16778038.6T patent/LT3359542T/lt unknown
- 2016-10-07 PE PE2018000507A patent/PE20181205A1/es unknown
- 2016-10-07 AU AU2016333721A patent/AU2016333721B2/en active Active
- 2016-10-07 ES ES16778038T patent/ES2873895T3/es active Active
- 2016-10-07 PT PT167780386T patent/PT3359542T/pt unknown
- 2016-10-07 RS RS20210700A patent/RS61936B1/sr unknown
- 2016-10-07 KR KR1020187013102A patent/KR20180058832A/ko not_active Application Discontinuation
- 2016-10-07 CN CN202110322485.6A patent/CN113214270A/zh active Pending
- 2016-10-07 MA MA50065A patent/MA50065B1/fr unknown
- 2016-10-07 TW TW105132652A patent/TWI737635B/zh active
- 2016-10-07 AR ARP160103098A patent/AR106314A1/es unknown
- 2016-10-07 BR BR112018007155-2A patent/BR112018007155B1/pt active IP Right Grant
- 2016-10-07 CN CN201680058768.1A patent/CN108137590B/zh active Active
- 2016-10-07 SI SI201631182T patent/SI3359542T1/sl unknown
- 2016-10-07 HU HUE16778038A patent/HUE054985T2/hu unknown
- 2016-10-07 UA UAA201804904A patent/UA123905C2/uk unknown
- 2016-10-07 EP EP16778038.6A patent/EP3359542B1/en active Active
-
2018
- 2018-03-13 IL IL258073A patent/IL258073B/en active IP Right Grant
- 2018-03-13 CL CL2018000666A patent/CL2018000666A1/es unknown
- 2018-04-04 CO CONC2018/0003565A patent/CO2018003565A2/es unknown
- 2018-04-06 PH PH12018500763A patent/PH12018500763A1/en unknown
- 2018-04-09 SA SA518391307A patent/SA518391307B1/ar unknown
- 2018-06-08 US US16/003,232 patent/US10717742B2/en active Active
- 2018-09-11 HK HK18111661.5A patent/HK1252365A1/zh unknown
-
2020
- 2020-04-09 US US16/844,473 patent/US10882866B1/en active Active
-
2021
- 2021-06-14 CY CY20211100524T patent/CY1124284T1/el unknown
- 2021-06-15 HR HRP20210960TT patent/HRP20210960T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
PE20190437A1 (es) | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR110405A1 (es) | Compuestos | |
AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
AR090862A1 (es) | Compuestos de tetrazolinona y su uso para combatir plagas | |
AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
AR087913A1 (es) | Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
AR090955A1 (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih | |
AR097436A1 (es) | Bis-amidopiridinas | |
UY36263A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso | |
AR090376A1 (es) | Compuestos herbicidas | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
AR091731A1 (es) | Antagonistas del receptor de mineralocorticoides | |
AR097935A1 (es) | Derivados de piridazinonas útiles como herbicidas | |
AR106397A1 (es) | Compuesto amida y agente para el control de plagas | |
AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina | |
AR109042A1 (es) | COMPUESTOS MODULARES DE RORg | |
AR102208A1 (es) | Compuestos de isotiazolo tiazina inhibidores de bace1 |